A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis-Reference-Cited by-同舟云学术

A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis

Published:2023-02-21 Issue:3 Volume:30 Page:313-320
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Planté-Bordeneuve Violaine¹²³^ORCID,Gorram Farida¹²³,Olsson Malin⁴⁵^ORCID,Anan Intissar⁴⁵^ORCID,Mazzeo Anna⁶,Gentile Luca⁶^ORCID,Cisneros-Barroso Eugenia⁷^ORCID,Gonzalez-Moreno Juan⁷,Losada Ines⁷,Waddington-Cruz Marcia⁸^ORCID,Pinto Luiz Felipe⁸,Parman Yeşim⁹,Fanen Pascale²³¹⁰,Alarcon Flora¹¹,Nuel Gregory¹²

Affiliation:

1. Department of Neurology, Henri Mondor University Hospital, APHP, Créteil, France

2. Paris Est-Créteil University, Créteil, France

3. Inserm U.955, Institut Mondor de Recherche Biomédicale (IMRB), Créteil, France

4. Department of Public Health and Clinical Medicine/Medicine, Umeå University, Umeå, Sweden

5. Wallenberg Centre for Molecular Medicine, Umeå University, Umeå, Sweden

6. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy

7. Research Health Institute of the Balearic Islands (IdISBa), Internal Medicine Department, Son Llàtzer University Hospital, Palma de Mallorca, Spain

8. CEPARM, Federal University of Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil

9. Department of Neurology, Neuromuscular Unit Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

10. Department of Genetics, Henri Mondor University Hospital, APHP, Créteil, France

11. Laboratory MAP5 UMR CNRS 8145 Paris University, Paris, France

12. Stochastics and Biology Group, Department of Probability and Statistics (LPSM, UMR CNRS 8001), Sorbonne University, Paris, France

Publisher

Informa UK Limited

Subject

Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2023.2178891

Reference40 articles.

1. Transthyretin familial amyloid polyneuropathy: an update

2. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee

3. Rowczenio D, Wechalekar A [Internet]. Mutations in hereditary amyloidosis; 2015. (cited 11 Oct 2021). Available from : http://amyloidosismutations.com/mut-attr.php.

4. Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis

5. Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy;Expert Opinion on Drug Discovery;2024-01-27

2. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal;Orphanet Journal of Rare Diseases;2023-10-12

3. Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca;Orphanet Journal of Rare Diseases;2023-08-31

4. Clinical model for Hereditary Transthyretin Amyloidosis age of onset prediction;Frontiers in Neurology;2023-07-17